Form 4: Avidity Biosciences Chief Program Officer Acquires Shares and Stock Options

Kathleen P. Gallagher, Chief Program Officer at Avidity Biosciences, acquired 25,000 shares of common stock and 50,000 stock options on January 6, 2025.

Summary

• Kathleen P. Gallagher, Chief Program Officer of Avidity Biosciences, filed a Form 4 indicating changes in her beneficial ownership of the company's securities.
• On January 6, 2025, Ms. Gallagher acquired 25,000 shares of common stock, which are restricted stock units (RSUs) that vest over four years.
• She also acquired 50,000 stock options with an exercise price of $31.42, vesting monthly over four years until January 6, 2029.
• Following these transactions, Ms. Gallagher directly owns 59,965 shares of common stock and 50,000 stock options.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of insider transactions, which is neither particularly positive nor negative. It reflects standard executive compensation practices.

Positives

• The acquisition of shares and options by a key executive could be seen as a positive sign of confidence in the company's future.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the biotechnology industry where stock-based compensation is a significant part of executive pay.

Comparison to Industry Standards

• Stock option grants and restricted stock units are standard forms of compensation for executives in the biotechnology industry, aligning their interests with those of shareholders.
• The vesting schedules for both the RSUs and stock options are typical, with vesting periods of four years.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment, as it indicates confidence from a key executive.

Key Dates

Keywords

Avidity Biosciences, RNA, Form 4, insider trading, stock options, restricted stock units, executive compensation, Kathleen P. Gallagher, beneficial ownership